



# 2025 SAMPLE CHARACTERISTICS




Between May-June, 2025, 53 participants recruited from Darwin, NT, were interviewed.



**46 years** **Male**


Median age and per cent who identified as male.



**81%** **25%**

Unemployed No fixed address


In the 2025 sample, 81% were unemployed and 25% had no fixed address.




- Injected heroin
- Injected methamphetamine
- Injected other illicit or non-prescribed drugs

Participants were recruited on the basis that they had injected drugs at least 6 days in the previous 6 months.

## INJECTING-RELATED RISKS AND HARMS




Few participants ( $n \leq 5$ ) reported receptive sharing in the past month, and few participants ( $n \leq 5$ ) reported distributive sharing.



**19%** **17%**


2024 2025

Percentage who reported re-using their own needles in the past month.




**30%**

Percentage who reported injecting someone else in the past month.



Few participants ( $n \leq 5$ ) reported having an injection-related health issue in the past month.


## OTHER HARMS



**55%** **38%**

Two or more drugs Stimulants and cannabis


In 2025, 55% reported using two or more drugs on the day preceding interview: the most commonly used combination of drug classes was stimulants and cannabis (38%).




**$n \leq 5$**   **$n \leq 5$**

2024 2025

In 2025, few participants ( $n \leq 5$ ) reported past year non-fatal overdose.



In 2025, 25% of participants reported a mental health problem in the 6 months preceding interview.




**78%** **64%**

2024 2025

Driving under the influence of non-prescribed drugs remained stable in 2025, relative to 2024.


## NALOXONE AND OTHER HARM REDUCTION STRATEGIES



**42%** **21%**


Knowledge of take home naloxone Past year naloxone obtainment

Knowledge of take-home naloxone and past year naloxone obtainment remained stable in 2025.




**69%**

Among those who reported obtaining naloxone at least once in their lifetime ( $n=9$ ), 69% had a median of one naloxone kit stored away at the time of interview.



**$n \leq 5$**

Few participants ( $n \leq 5$ ) reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.




**$n \leq 5$**  **81%**


Drug treatment Health service access

Percentage who reported current drug treatment and health service access for AOD support in the past six months.

OPIOIDS




Morphine was the most commonly used opioid in 2025, with 15% reporting non-prescribed use.



Participants who had recently used non-prescribed morphine reported use on a median of 102 days.




Few participants (n≤5) reported recent heroin use in 2025 (n≤5 in 2024).




No participants reported recent use of non-prescribed fentanyl in 2025 (n≤5 in 2024).

METHAMPHETAMINE

FORM of methamphetamine



Past 6 month use of methamphetamine. No participants reported recent use of powder or base methamphetamine in 2025.




Of those who had recently used any form of methamphetamine, 82% reported weekly or more frequent use, stable from 2024 (90%).




\$100 \$100  
2024 2025

The median reported price for a point of methamphetamine crystal.




Percentage who perceived methamphetamine crystal as being 'easy' or 'very easy' to obtain.


CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS




Past 6 month use remained stable in 2025 (60%) relative to 2024 (69%).



Of those who had recently used non-prescribed cannabis/cannabinoid-related products, 56% reported daily use, stable from 2024 (77%).




All participants who reported recent use of non-prescribed cannabis and/or cannabinoid-related products reported using hydroponic cannabis. Few participants (n≤5) reported recent use of any other forms.



Percentage who perceived hydroponic cannabis as being 'easy' or 'very easy' to obtain.

PAST 6 MONTH USE OF OTHER DRUGS


Any new psychoactive substance



Non-prescribed benzodiazepines



Non-prescribed pregabalin



GHB/GBL/1,4-BD

